FDA might mandate drug training

Perhaps triplicate prescriptions are not enough of a safety measure when it comes to powerful narcotics. At least, that's what the FDA might be thinking. The agency is considering mandatory training for clinicians who prescribe certain narcotic medications, including methadone, fentanyl and some versions of oxycodone.

It's a move that would be controversial and one that the FDA cannot make in a vacuum, according to Bob Rappaport, the agency's director for the division of Anesthesia, Analgesia and Rheumatology Products, as states usually have jurisdiction over regulatory and education issues when it comes to physicians.

As it stands, a state medical license and a simple registration with the Drug Enforcement Administration are all that are necessary for a physician to prescribe narcotics. At present, states like California that require additional training are the exception rather than the norm.  

- read the full story in the New York Times

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.